Safety Extension Study for Patients Previously Treated with Trastuzumab Emtansine Alone or with Other Cancer Therapies

Inclusion Criteria

• Completed or are currently receiving trastuzumab emtansine treatment in a previous study and had their last dose within 6 weeks before starting this extension study.
• Were in the control group of a specific previous study and had disease progression during the transition to this extension study.
• The study doctor believes the patient may continue to benefit from the treatment.
• Women who can become pregnant and men with partners who can become pregnant must use effective non-hormonal birth control during the study and for several months after the last dose.
• Men with pregnant partners should use condoms during the pregnancy and should not donate sperm during this time.

Exclusion Criteria

• Had side effects in the previous study that led to stopping trastuzumab emtansine treatment.
• Have ongoing serious side effects from the previous study.
• Experienced disease progression on trastuzumab emtansine treatment in the previous study, except for certain cases.
• Have severe nerve damage or heart problems.
• Have severe breathing difficulties or need continuous oxygen therapy.
• Have uncontrolled serious health conditions.
• Had major surgery or a significant injury within 28 days before joining this study.
• Are currently pregnant or breastfeeding.
• Have received other cancer treatments since the last dose in the previous study.
• Have allergies to trastuzumab emtansine or related treatments.
• Are unable or unwilling to follow the study requirements.